Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M17,165Revenue $M7,143Net Margin (%)3.9Z-Score0.9
Enterprise Value $M21,171EPS $-0.1Operating Margin %4.3F-Score6
P/E(ttm))61.3Cash Flow Per Share $1.5Pre-tax Margin (%)1.4Higher ROA y-yY
Price/Book2.610-y EBITDA Growth Rate %0Quick Ratio1.2Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %0Current Ratio1.7Lower Leverage y-yN
Price/Cash Flow3.8y-y EBITDA Growth Rate %51.4ROA % (ttm)1.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)4.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,326ROI % (ttm)-9.4Gross Margin Increase y-yY

Gurus Latest Trades with BSX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BSXVanguard Health Care Fund 2014-09-30 Add0.25%$11.92 - $13.29
($12.59)
$ 12.943%Add 19.88%51,242,050
BSXRay Dalio 2014-09-30 Buy 0.01%$11.92 - $13.29
($12.59)
$ 12.943%New holding, 61384 sh.61,384
BSXLeon Cooperman 2014-09-30 Sold Out -1.1%$11.92 - $13.29
($12.59)
$ 12.943%Sold Out0
BSXVanguard Health Care Fund 2014-06-30 Add0.2%$12.58 - $13.77
($13.01)
$ 12.940%Add 16.19%42,743,200
BSXRay Dalio 2014-06-30 Sold Out $12.58 - $13.77
($13.01)
$ 12.940%Sold Out0
BSXLeon Cooperman 2014-06-30 Reduce-0.35%$12.58 - $13.77
($13.01)
$ 12.940%Reduce -23.25%6,549,479
BSXRay Dalio 2014-03-31 Reduce-0.01%$11.91 - $13.98
($13.08)
$ 12.94-1%Reduce -70.15%36,884
BSXMichael Price 2013-12-31 Add0.47%$11.18 - $12.38
($11.81)
$ 12.9410%Add 17.65%2,000,000
BSXRay Dalio 2013-12-31 Buy 0.01%$11.18 - $12.38
($11.81)
$ 12.9410%New holding, 123584 sh.123,584
BSXLeon Cooperman 2013-12-31 Reduce-0.88%$11.18 - $12.38
($11.81)
$ 12.9410%Reduce -36.64%8,533,099
BSXDodge & Cox 2013-12-31 Reduce-0.18%$11.18 - $12.38
($11.81)
$ 12.9410%Reduce -22.34%45,938,468
BSXJoel Greenblatt 2013-12-31 Sold Out -0.01%$11.18 - $12.38
($11.81)
$ 12.9410%Sold Out0
BSXLeon Cooperman 2013-09-30 Reduce-0.42%$9.15 - $11.99
($10.83)
$ 12.9420%Reduce -18.19%13,467,416
BSXDodge & Cox 2013-09-30 Reduce-0.25%$9.15 - $11.99
($10.83)
$ 12.9420%Reduce -27.68%59,157,107
BSXVanguard Health Care Fund 2013-09-30 Reduce-0.24%$9.15 - $11.99
($10.83)
$ 12.9420%Reduce -15.74%38,240,700
BSXCharles Brandes 2013-09-30 Sold Out -0.07%$9.15 - $11.99
($10.83)
$ 12.9420%Sold Out0
BSXJoel Greenblatt 2013-09-30 Reduce-0.02%$9.15 - $11.99
($10.83)
$ 12.9420%Reduce -69.22%18,744
BSXCharles Brandes 2013-06-30 Reduce-1.54%$7.09 - $9.64
($8.48)
$ 12.9453%Reduce -96.31%624,088
BSXDodge & Cox 2013-06-30 Reduce-0.14%$7.09 - $9.64
($8.48)
$ 12.9453%Reduce -14.79%81,801,130
BSXJoel Greenblatt 2013-06-30 Reduce-0.03%$7.09 - $9.64
($8.48)
$ 12.9453%Reduce -51.28%60,894
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BSX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BSX Ray Dalio 2014-09-3061,38400.01New Buy
BSX Vanguard Health Care Fund 2014-09-3051,242,0503.871.5+19.88%
BSX Michael Price 2014-09-302,000,0000.152.9
BSX Dodge & Cox 2014-09-3044,458,3383.350.5-0.92%
BSX PRIMECAP Management 2014-09-3047,079,1993.550.59-2.83%
BSX Mario Gabelli 2014-09-301,704,0360.130.11-4.58%
BSX Leon Cooperman 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BSX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lance Jean FittererSVP & Chief Compliance Officer 2014-11-10Sell15,000$13.4-3.43view
LUDWIG EDWARD JDirector 2014-11-10Buy10,000$13.38-3.29view
Sununu John EDirector 2014-11-05Sell8,997$13.38-3.29view
MARIO ERNESTDirector 2014-11-03Sell10,000$13.3-2.71view
MARIO ERNESTDirector 2014-10-08Sell10,000$12.067.3view
MARIO ERNESTDirector 2014-09-02Sell10,000$12.62.7view
Phalen Michael P.EVP & President, MedSurg 2014-08-15Sell11,471$12.582.86view
MARIO ERNESTDirector 2014-08-01Sell10,000$12.582.86view
Pierce David ASVP and President, Endoscopy 2014-07-30Sell157$12.97-0.23view
Phalen Michael P.EVP & President, MedSurg 2014-07-15Sell67,500$13.04-0.77view

Press Releases about BSX :

    Quarterly/Annual Reports about BSX:

    News about BSX:

    Articles On GuruFocus.com
    Diamond Hill Capital Comments on Boston Scientific Corp Oct 17 2014 
    Diamond Hill Capital Comments on Boston Scientific Corp Jul 25 2014 
    Diamond Hill Capital Comments on Boston Scientific Corp Jun 26 2014 
    Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 
    Diamond Hill Capital Comments on Boston Scientific Corp Jan 15 2014 
    Vanguard Health Care Fund Selling Update Oct 30 2013 
    Diamond Hill Funds Q3 Market Review and Large-Cap Fund Commentary Oct 29 2013 
    Weekly CFO Sells Highlight: BSX, RKUS, MCRL, LRAD and SWKS Sep 08 2013 
    Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
    comment on BSX May 22 2013 


    More From Other Websites
    Boston Scientific to pay damages in transvaginal mesh case Nov 20 2014
    Boston Scientific Vaginal-Mesh Victims Win $18.5 Million Nov 20 2014
    J&J demands $7.2 bln from Boston Scientific as trial begins Nov 20 2014
    Boston Scientific ordered to pay $14.5 mln for transvaginal mesh injuries Nov 20 2014
    Boston Scientific (BSX) Spotted As Roof Leaker Today Nov 20 2014
    Boston Scientific Earns Top Marks In Corporate Equality Index Nov 19 2014
    Boston Scientific Put Mesh Sales Ahead of Safety: Lawyer Nov 19 2014
    Boston Scientific (BSX) Is Water-Logged And Getting Wetter Today Nov 19 2014
    New Data From Evolve Clinical Program Demonstrate SYNERGY™ Bioabsobable Polymer Stent Meets Key... Nov 19 2014
    New Data From Evolve Clinical Program Demonstrate SYNERGY™ Bioabsobable Polymer Stent Meets Key... Nov 19 2014
    Boston Scientific stent succeeds in study aimed at U.S. approval Nov 19 2014
    Will Boston Scientific (BSX) Stock Be Hurt Today by This Multi-Billion Dollar Lawsuit? Nov 19 2014
    J&J seeks over $5 bln in damages from Boston Scientific at trial Nov 19 2014
    J&J seeks over $5 billion in damages from Boston Scientific at trial Nov 19 2014
    J&J seeks over $5 bln in damages from Boston Scientific at trial Nov 19 2014
    Watch Out: Barbarians At The Gate For Boston Scientific (BSX) Nov 18 2014
    Boston Scientific's Symphion System Marks 1st US Surgery Nov 18 2014
    First U.S. Procedures Completed With The Symphion™ Hysteroscopic Tissue Removal System Nov 17 2014
    First U.S. Procedures Completed With The Symphion™ Hysteroscopic Tissue Removal System Nov 17 2014
    Extended anti-clotting therapy cut heart attacks after stent -study Nov 16 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK